Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Bricanyl Turbuhaler
Terbutaline Turbuhaler · 1 trial · 1 indication
FEV1 (Forced Expiratory Volume in 1 second) AUC 0-4 hours after drug inhalation
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Terbutaline Turbuhaler® 0.4mg + pMDI placebo pMDI ⇒salbutamol pMDI 200 μg +placebo Turbuhaler® |
| 2 | EXPERIMENTAL | salbutamol pMDI 200 μg +placebo Turbuhaler® ⇒Terbutaline Turbuhaler® 0.4mg + pMDI placebo pMDI |
| Name | Type | Description |
|---|---|---|
| Terbutaline Turbuhaler® | DRUG | 0.4 mg, inhalation, single dose |
| Salbutamol pMDI | DRUG | 200 μg, inhalation, single dose |
| pMDI placebo pMDI | OTHER | Placebo pMDI 2 inhalations |
| Placebo Turbuhaler® | OTHER | Placebo Turbuhaler 1 inhalation |
Inclusion Criteria: * On ICS for at least 3 months from Visit 2 and with a prescribed constant dose during the 4 weeks prior to Visit 2 * Forced Expiratory Volume in 1 Second (FEV1) of at least 50 % of predicted normal value pre-bronchodilator * Reversible airway obstruction according to reversibil...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
Terbutaline Turbuhaler is an inhaled asthma medicine developed by AstraZeneca PLC. It is a small molecule beta-2 adrenergic receptor agonist delivered as a dry powder through the Turbuhaler device, and it is intended for patients with asthma. It has been studied in a Phase 3 trial in Japan.
Terbutaline Turbuhaler works as an agonist of ADRB2, the beta-2 adrenergic receptor. By activating this receptor in the airways, terbutaline promotes bronchodilation, helping to relax airway smooth muscle and improve airflow in patients with asthma. The drug is a small molecule delivered by inhalation.
Terbutaline Turbuhaler is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the company behind the Turbuhaler dry powder inhaler technology used to deliver this asthma therapy.
Terbutaline Turbuhaler is in Phase 3 development for asthma. It is an investigational product and is not described as approved. The Phase 3 trial NCT01096017 has been completed, and no active trials are currently listed for this asset.
Terbutaline Turbuhaler has been evaluated in one completed Phase 3 trial, NCT01096017, titled a study to investigate the relative efficacy of Terbutaline Turbuhaler and salbutamol pressurized metered dose inhaler. The single-blind, controlled study enrolled 24 participants with asthma in Japan, including patients aged 16 years and older.